Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.
Anti-VEGFR-3 therapy and lymph node metastasis [corrected].
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
VEGFR3: a new target for antiangiogenesis therapy?
VEGFR1-activity-independent metastasis formation.
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Antiangiogenic therapy for cancer: current and emerging concepts.
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.
Targeted therapy in rectal cancer.
Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required?
Transvascular and interstitial transport in tumors.
Geometric resistance and microvascular network architecture of human colorectal carcinoma.
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Anti-VEGF treatment improves neurological function in tumors of the nervous system.
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55a Complex the Answer?